Lexicon Pharma (LXRX) Misses Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.22 +2.78%
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.34), $0.04 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $11.11 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- Qualcomm unveils Dragonfly CPU, signs Meta as first data center customer
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
